ES2185770T3 - Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce. - Google Patents

Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.

Info

Publication number
ES2185770T3
ES2185770T3 ES96909384T ES96909384T ES2185770T3 ES 2185770 T3 ES2185770 T3 ES 2185770T3 ES 96909384 T ES96909384 T ES 96909384T ES 96909384 T ES96909384 T ES 96909384T ES 2185770 T3 ES2185770 T3 ES 2185770T3
Authority
ES
Spain
Prior art keywords
monoclonal antibody
cell line
produces
human
specific monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909384T
Other languages
English (en)
Inventor
Chang Yuil Kang
Joong Gon Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Application granted granted Critical
Publication of ES2185770T3 publication Critical patent/ES2185770T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN ANTICUERPO MONOCLONAL ESPECIFICO PARA 4-1BB HUMANO, MOLECULA ACCESORIA, QUE ES EXPRESADA DE FORMA SELECTIVA EN CELULAS T ACTIVADAS; POLINUCLEOTIDOS QUE CODIFICAN LAS REGIONES VARIABLES DEL ANTICUERPO MONOCLONAL Y SECUENCIAS DE AMINOACIDO DEDUCIDAS DE LOS MISMOS; UNA LINEA CELULAR HIBRIDOMA QUE PRODUCE EL ANTICUERPO MONOCLONAL; UN PROCESO PARA PREPARAR LA LINEA CELULAR; Y UN AGENTE INMUNOSUPRESOR QUE COMPRENDE EL ANTICUERPO MONOCLONAL O UNA VARIANTE DEL MISMO.
ES96909384T 1995-04-08 1996-04-06 Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce. Expired - Lifetime ES2185770T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR19950008176 1995-04-08

Publications (1)

Publication Number Publication Date
ES2185770T3 true ES2185770T3 (es) 2003-05-01

Family

ID=19411779

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909384T Expired - Lifetime ES2185770T3 (es) 1995-04-08 1996-04-06 Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.

Country Status (9)

Country Link
US (1) US5928893A (es)
EP (1) EP0766745B1 (es)
JP (1) JP2911056B2 (es)
AT (1) ATE226641T1 (es)
DE (1) DE69624436T2 (es)
DK (1) DK0766745T3 (es)
ES (1) ES2185770T3 (es)
PT (1) PT766745E (es)
WO (1) WO1996032495A1 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002904A9 (en) * 1988-11-07 2006-01-05 Kwon Byoung S Receptor and related products and methods
US6362325B1 (en) * 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US20060063923A1 (en) * 1992-07-30 2006-03-23 Kwon Byoung S 4-1BB peptides and methods for use
CA2172165C (en) * 1993-09-16 2003-12-02 Byoung S. Kwon Human receptor h4-1bb
JP2001502325A (ja) * 1996-10-11 2001-02-20 ブリストル―マイヤーズ・スクイブ・カンパニー 免疫調整の方法および組成物
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
US20030096976A1 (en) * 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
US20040001863A1 (en) * 1998-12-03 2004-01-01 Shau-Chi Chi Immortal cell line derived from grouper Epinephelus coioides and its applications therein
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
EP1294699B1 (en) 2000-05-12 2016-04-13 Genzyme Corporation Modulators of tnf- alpha signalling
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
ES2328025T3 (es) 2001-10-09 2009-11-06 Mayo Foundation For Medical Education And Research Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
CA2492561A1 (en) * 2002-07-15 2004-01-22 Mayo Foundation For Medical Education And Research Treatment and prophylaxis with 4-1bb-binding agents
PL375144A1 (en) * 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
EP1388544A1 (en) * 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
AU2003290059A1 (en) * 2002-12-16 2004-07-09 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
EP3428191A1 (en) 2004-10-06 2019-01-16 Mayo Foundation for Medical Education and Research B7-h1 and pd-1 in treatment of renal cell carcinoma
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
JP5328019B2 (ja) * 2005-10-21 2013-10-30 レヴォ バイオロジクス インコーポレイテッド 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
WO2007082154A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
US20110229460A1 (en) * 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US8324352B2 (en) 2009-12-07 2012-12-04 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
EP2970445A4 (en) 2013-03-12 2017-02-22 Decimmune Therapeutics Inc. Humanized anti-n2 antibodies
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3470081A1 (en) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US10780080B2 (en) 2016-11-23 2020-09-22 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
US20200121719A1 (en) 2017-01-06 2020-04-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
EP3635097A1 (en) 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
KR20200035966A (ko) 2017-07-11 2020-04-06 콤파스 테라퓨틱스 엘엘씨 인간 cd137에 결합하는 작동자 항체 및 이의 용도
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
TW201932491A (zh) * 2018-01-22 2019-08-16 大陸商江蘇恆瑞醫藥股份有限公司 抗４－１ｂｂ抗體、其抗原結合片段及其醫藥用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019160829A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
MX2020010264A (es) 2018-03-29 2020-11-06 Iovance Biotherapeutics Inc Procesos para la produccion de linfocitos infiltrantes en tumor y usos de los mismos en inmunoterapia.
EP3773720A4 (en) * 2018-04-10 2022-01-05 Wuxi Biologics (Shanghai) Co. Ltd. MONOCLONAL ANTIBODY AGAINST HUMAN 4-1BB, ITS PREPARATION PROCESS, AND ITS USE
KR20210005138A (ko) 2018-04-27 2021-01-13 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 확장 및 유전자 편집을 위한 폐쇄 방법 및 면역요법에서의 그의 용도
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
JP2022501038A (ja) 2018-09-20 2022-01-06 アイオバンス バイオセラピューティクス，インコーポレイテッド 凍結保存腫瘍サンプルからのｔｉｌの拡大培養
EP3877511A1 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
AU2019377422A1 (en) 2018-11-05 2021-05-27 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
JP2022506586A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の産生のためのプロセスおよび免疫療法におけるその使用
SG11202104630PA (en) 2018-11-05 2021-06-29 Iovance Biotherapeutics Inc Selection of improved tumor reactive t-cells
JP2022514023A (ja) 2018-12-19 2022-02-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
MX2021011608A (es) 2019-03-29 2021-12-10 Myst Therapeutics Llc Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2022542670A (ja) * 2019-07-26 2022-10-06 エービーエル バイオ インコーポレイテッド 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用
JP2022553389A (ja) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
CN115023270A (zh) 2019-11-27 2022-09-06 迈斯特治疗公司 使用调节剂产生肿瘤反应性t细胞组合物的方法
US20230220341A1 (en) 2019-12-11 2023-07-13 lovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
CN115427438A (zh) 2020-02-27 2022-12-02 迈斯特治疗公司 肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2023524108A (ja) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
US20230242674A1 (en) * 2020-07-09 2023-08-03 Lankenau Institute For Medical Research Compositions comprising antibodies to human ido-2
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
TW202241468A (zh) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CN117279506A (zh) 2021-03-05 2023-12-22 艾欧凡斯生物治疗公司 肿瘤储存及细胞培养组合物
BR112023021665A2 (pt) 2021-04-19 2023-12-19 Iovance Biotherapeutics Inc Método para tratar um câncer, e, composição
CA3219148A1 (en) 2021-05-17 2022-11-24 Frederick G. Vogt Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202327631A (zh) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者
CA3232700A1 (en) 2021-09-24 2023-03-30 Rafael CUBAS Expansion processes and agents for tumor infiltrating lymphocytes
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU6827094A (en) * 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
CA2172165C (en) * 1993-09-16 2003-12-02 Byoung S. Kwon Human receptor h4-1bb

Also Published As

Publication number Publication date
PT766745E (pt) 2003-02-28
DE69624436T2 (de) 2003-08-28
DK0766745T3 (da) 2002-11-25
WO1996032495A1 (en) 1996-10-17
US5928893A (en) 1999-07-27
JPH09509067A (ja) 1997-09-16
EP0766745A1 (en) 1997-04-09
EP0766745B1 (en) 2002-10-23
DE69624436D1 (de) 2002-11-28
ATE226641T1 (de) 2002-11-15
JP2911056B2 (ja) 1999-06-23

Similar Documents

Publication Publication Date Title
ES2185770T3 (es) Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
SV1996000033A (es) Isotiazolonas
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
PE20050205A1 (es) Moleculas de union a cd20
DK0711140T3 (da) Antimykotisk opløsning til negle
DE69432704D1 (de) Verfahren zur Herstellung von humanen Relaxin
ES2194846T3 (es) Peptidos marcados con tecnecio-99m para obtencion de imagenes de inflamacion.
PA8464901A1 (es) Procesos para la sintesis de 1,3-dioles
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
SV1996000031A (es) Proceso y formas de cristal de 2-metil-tieno-benzodiacepina. ref. x-8917a
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
ECSP066450A (es) AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2d
UY24651A1 (es) Método para la síntesis de analogos de la hormona paratiroidea y del peptido relacionado con la hormona paratiroidea.
ATE233173T1 (de) Gebrauch von vernetzten polyolefinmaterial in druckleitungen
DE60214495D1 (de) Kosmetische Zusammensetzung zur Haarbehandlung, die ein haarfixierendes nichtassoziatives Polyurethan und ein anionisches oder nichtionisches assoziatives Polyurethan enthält und kosmetisches Behandlungsverfahren
TR199802512T2 (xx) Plastik par�alar�n asamblaj�n�n y�ksek h�zda asamblaj� i�in proses.
NO995278L (no) Fremgangsmåte og apparat for produksjon av strekkinnpakningsplastfilm
HUP0001644A2 (hu) Eljárás kitinázok előállítására
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
ATE391113T1 (de) Verfahren zur herstellung von pentafluorethan
PT633928E (pt) Microrganismos processo de preparacao e utilizacao
ES2121204T3 (es) Preparacion de fluoro-nucleosidos e intermedios para su uso en ella.
ES2138363T3 (es) Procedimiento para la obtencion de dolastatina 15 y sus productos intermedios.
ES2176475T3 (es) Composiciones de inhibidor bowman-birk para el tratamiento de enferm edades inflamatorias.
ES2039250T3 (es) Tratamiento de materiales de lana.